SAB Biotherapeutics shares rise 10.22% intraday after appointing experienced biopharma leaders to board to advance T1D candidate.

SAB Biotherapeutics (SABS) surged 10.22% intraday following the announcement of two strategic board appointments: David Zaccardelli, a biopharma executive with 20+ years of experience including leading the successful launch of Ohtuvayre, as Board Chair, and Rita Jain, a rheumatologist with extensive autoimmune disease drug development expertise, as an independent director. The appointments, effective January 7, 2026, were highlighted by CEO Samuel Reich as validating SAB BIO’s growth trajectory and advancing its lead candidate, SAB-142, a potential disease-modifying therapy for type 1 diabetes. Zaccardelli’s track record in commercializing biotech products and Jain’s clinical and regulatory experience in autoimmune therapies were cited as critical to accelerating SAB-142’s development and preparing for potential commercialization, directly linking the news to the stock’s sharp intraday rally.